Yoshiyuki Ohsugi1, Nobuyuki Tsuchimoto. Show Affiliations » 1. ohsugiysy@chugai-pharm.co.jp
Abstract
Entities: Chemical Disease Species
Mesh: See more » AnimalsAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/metabolismAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedBinding, CompetitiveCastleman Disease/drug therapyCastleman Disease/etiologyCastleman Disease/pathologyCell Proliferation/drug effectsClinical Trials as TopicDrug DesignHumansInterleukin-6/physiologyLymph Nodes/cytologyLymph Nodes/pathologyReceptors, Interleukin-6/immunologyReceptors, Interleukin-6/metabolismRecombinant Proteins/therapeutic useSignal Transduction
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedInterleukin-6Receptors, Interleukin-6Recombinant Proteinstocilizumab
Year: 2005 PMID: 16462093 DOI: 10.1254/fpj.126.419
Source DB: PubMed Journal: Nihon Yakurigaku Zasshi ISSN: 0015-5691